Correction to: FDG-PET/CT in colorectal cancer: potential for vascular-metabolic imaging to provide markers of prognosis

Abstract Purpose This study assesses the potential for vascular-metabolic imaging with FluoroDeoxyGlucose (FDG)–Positron Emission Tomography/Computed Tomography (PET/CT) perfusion to provide markers of prognosis specific to the site and stage of colorectal cancer. Methods This prospective observational study comprised of participants with suspected colorectal cancer categorized as either (a) non-metastatic colon cancer (M0colon), (b) non-metastatic rectal cancer (M0rectum), or (c) metastatic colorectal cancer (M+). Combined FDG-PET/CT perfusion imaging was successfully performed in 286 participants (184 males, 102 females, age: 69.60 ± 10 years) deriving vascular and metabolic imaging parameters. Vascular and metabolic imaging parameters alone and in combination were investigated with respect to overall survival. Results A vascular-metabolic signature that was significantly associated with poorer survival was identified for each patient group: M0colon – high Total Lesion Glycolysis (TLG) with increased Permeability Surface Area Product/Blood Flow (PS/BF), Hazard Ratio (HR) 3.472 (95% CI: 1.441–8.333), p = 0.006; M0rectum – high Metabolic Tumour Volume (MTV) with increased PS/BF, HR 4.567 (95% CI: 1.901–10.970), p = 0.001; M+ participants, high MTV with longer Time To Peak (TTP) enhancement, HR 2.421 (95% CI: 1.162–5.045), p = 0.018. In participants with stage 2 colon cancer as well as those with stage 3 rectal cancer, the vascular-metabolic signature could stratify the prognosis of these participants. Conclusion Vascular and metabolic imaging using FDG-PET/CT can be used to synergise prognostic markers. The hazard ratios suggest that the technique may have clinical utility.

Download Full-text

Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer

Clinical Nuclear Medicine ◽

10.1097/rlu.0000000000002611 ◽

2019 ◽

Vol 44 (7) ◽

pp. 578-579 ◽

Cited By ~ 1

Author(s):

Karim Amrane ◽

Luc Ollivier ◽

Pierre-Yves Salaun ◽

Jean-Philippe Metges ◽

Ronan Abgral

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Fdg Pet ◽

Metabolic Response ◽

Line Treatment ◽

Second Line ◽

Complete Metabolic Response ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

Integrated18F-FDG PET/CT and Perfusion CT of Primary Colorectal Cancer: Effect of Inter- and Intraobserver Agreement on Metabolic-Vascular Parameters

American Journal of Roentgenology ◽

10.2214/ajr.11.7823 ◽

2012 ◽

Vol 199 (5) ◽

pp. 1003-1009 ◽

Cited By ~ 11

Author(s):

Vicky Goh ◽

Manu Shastry ◽

Alec Engledow ◽

Robert Kozarski ◽

Jacqui Peck ◽

...

Keyword(s):

Colorectal Cancer ◽

Fdg Pet ◽

Perfusion Ct ◽

Intraobserver Agreement ◽

Primary Colorectal Cancer ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

Bone Metastases on 18F-FDG PET/CT Imaging in Patients with Colorectal Cancer. Does Bone Scintigraphy Still Have a Role?

Eurasian Journal of Medical Investigation ◽

10.14744/ejmi.2021.86631 ◽

2021 ◽

Author(s):

Sevda Saglampinar Karyagar

Keyword(s):

Colorectal Cancer ◽

Bone Metastases ◽

Bone Scintigraphy ◽

Fdg Pet ◽

Ct Imaging ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Download Full-text

Improvement of the diagnostic accuracy of lymph node metastases of colorectal cancer in 18F-FDG-PET/CT by optimizing the iteration number for the image reconstruction

Annals of Nuclear Medicine ◽

10.1007/s12149-007-0141-9 ◽

2008 ◽

Vol 22 (6) ◽

pp. 465-473 ◽

Cited By ~ 9

Author(s):

Kazumasa Inoue ◽

Takashi Sato ◽

Hideaki Kitamura ◽

Masaaki Ito ◽

Yoshiyuki Tsunoda ◽

...

Keyword(s):

Colorectal Cancer ◽

Lymph Node ◽

Diagnostic Accuracy ◽

Lymph Node Metastases ◽

Fdg Pet ◽

Pet Ct ◽

Node Metastases ◽

18F Fdg ◽

Iteration Number ◽

Fdg Pet Ct

Download Full-text

The role of 18F-FDG PET/CT in the management of large-vessel vasculitis: applications and limitations in clinical practice

Italian Journal of Medicine ◽

10.4081/itjm.2011.249 ◽

2012 ◽

pp. 249-254

Author(s):

Maria V. Mattoli ◽

Giorgio Treglia ◽

Lucia Leccisotti ◽

Alessandro Giordano

Keyword(s):

Clinical Practice ◽

Fdg Pet ◽

False Negative ◽

Large Vessel Vasculitis ◽

Large Vessel ◽

Metabolic Imaging ◽

Small Vessel Vasculitis ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct

Introduction: 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) plays a key role in oncology, and it is now being used increasingly to diagnose, characterize, and monitor disease activity in inflammatory disorders, including vasculitis. Unfortunately, its role in the management of vasculitis is still not well-defined, and clinicians are often unsure how this metabolic imaging technique should be used in these diseases, although its usefulness in diagnosing large-vessel vasculitis has been clearly demonstrated. Materials and methods: We reviewed the literature about the use of PET/CT in the management of vasculitis in an attempt to identify the applications and the limitations of this technique in clinical practice. Results and discussion: Our literature review revealed that 18F-FDG PET/CT is a useful tool for diagnosing vasculitis (especially when the symptoms of the disease are non-specific); guiding biopsy procedures (areas with high glucose consumption); evaluating disease extension; and monitoring treatment responses. The main limitations of this method are the relatively low spatial resolution of the tomograph, which can lead to false-negative results in the presence of small-vessel vasculitis, and risk of false positive results, especially those related to the presence of atherosclerosis and to post-treatment vascular remodeling.

Download Full-text